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Despite all the advances made in the treatment
and management, tuberculosis (TB) still remains as
one of the main public health problems, particularly
in the developing countries. India accounts for nearly
30 per cent of the global TB burden1.
Although the phenomenon of drug resistance in
Mycobacterium tuberculosis was observed as early as
50 yr ago, the current threat is due to the emergence of
strains resistant to the two most potent anti-TB drugs
viz., isoniazid (H) and rifampicin (R) (multidrug
resistant-tuberculosis, MDR-TB).  The response of
patients with MDR-TB to treatment is poor and the
mortality rate is usually high.  Since these patients need
to be treated with expensive and toxic second line drugs,
and may require hospitalization to manage their toxic
reactions and other complications, they require a sizeable
proportion of health care resources.
Further, an alarming increase in infection due to
the human immunodeficiency virus (HIV) has
accelerated this situation and it is believed that, as of
now, about 3.5 million people in India are infected
with HIV2. There is a grave concern in India regarding
the increase in HIV-associated TB and the emergence
of MDR-TB in both magnitude and severity of TB
epidemic.
Definition of drug resistance
Drug resistance in mycobacteria is defined as a
decrease in sensitivity to a sufficient degree to be
reasonably certain that the strain concerned is
different from a sample of wild strains of human type
that have never come in contact with the drugs3.
Types of drug resistance
Drug resistance in TB may be broadly classified
as primary or acquired.  When drug resistance is
demonstrated in a patient who has never received anti-
TB treatment previously, it is termed primary
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The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance
to the two most potent drugs viz., isoniazid and rifampicin. The level of initial drug resistance
is an epidemiological indicator to assess the success of the TB control programme. Though
drug resistance in TB has frequently been reported from India, most of the available information
is localized, sketchy or incomplete. A review of the few authentic reports indicates that there is
no clear evidence of an increase in the prevalence of initial resistance over the years. However,
a much higher prevalence of acquired resistance has been reported from several regions, though
based on smaller numbers of patients.  A strong TB control programme and continuous
surveillance studies employing standardized methodology and rigorous quality control
measures will serve as useful parameters in the evaluation of current treatment policies as well
as the management of multidrug resistant  (MDR) TB cases.
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resistance.  Acquired resistance is that which occurs
as a result of specific previous treatment.  The level
of primary resistance in the community is considered
to reflect the efficacy of control measures in the past,
while the level of acquired resistance is a measure of
on-going TB control measures. However, the World
Health Organization (WHO) and the  International
Union Against Tuberculosis and Lung Diseases
(IUATLD), in the light of discussions in several
international fora, have replaced the term primary
resistance by the term “drug resistance among new
cases” and acquired resistance by the term “drug
resistance among previously treated cases”4.
Causes of drug resistance
The emergence of drug resistance in
M.tuberculosis has been associated with a variety of
management, health provider and patient-related
factors. These include (i) deficient or deteriorating
TB control programmes resulting in inadequate
administration of effective treatment;  (ii) poor case
holding, administration of sub-standard drugs,
inadequate or irregular drug supply and lack of
supervision; (iii) ignorance of health care workers in
epidemiology, treatment and control; (iv) improper
prescription of regimens; (v) interruption of
chemotherapy due to side effects; (vi) non-adherence
of patients to the prescribed drug therapy; (vii)
availability of anti-TB drugs across the counter,
without prescription; (viii) massive bacillary load;
(ix) illiteracy and low socio-economic status of the
patients; (x) the epidemic of HIV infection; (xi)
laboratory delays in identification and susceptibility
testing of M. tuberculosis isolates; (xii) use of non-
standardized laboratory techniques, poor quality drug
powders and lack of quality control measures; and
(xiii) use of anti-TB drugs for indications other than
tuberculosis.
Mechanism and transmission of drug resistance
Drug resistance in M. tuberculosis occurs by
random, single step, spontaneous mutation at a low
but predictable frequency, in large bacterial
populations. The probability of incidence of drug
resistant mutants is 10-8 for rifampicin, while for
isoniazid and some of the other commonly used drugs
it is 10-6. Therefore, the probability for resistance to
both isoniazid and rifampicin to develop is 10-14,
which is much larger than the number of organisms
present in a medium sized cavity in a patient with
open pulmonary TB.
Although for several years, drug resistant strains
of M. tuberculosis were considered to be less
infectious than the drug susceptible ones, recent
studies have demonstrated that the drug resistant
mutants are equally infectious and can cause severe
disease in an individual exposed to the same5.
Detection of drug resistance
The conventional methods of culture,
identification and drug susceptibility testing of the
isolated organism require a minimum of 10-12 wk.
Although most widely used, the long waiting period
in obtaining the results by these methods may delay
the initiation of proper treatment, resulting in the
patient transmitting drug-resistant infection in the
community. The use of direct sensitivity tests,
especially to isoniazid and rifampicin has resulted in
a saving of at least 4 wk in obtaining the resistance
status6, 7.  However, this method is not very useful in
smear-negative and paucibacillary specimens.
Several newer methods including molecular
diagnostics have resulted in cutting down the time
interval between collection of the specimen and the
receipt of results to 2-3 wk or even less. However,
these methods require considerable technical
expertise and impose financial constraints in a routine
laboratory set up in the developing nations.
WHO/IUATLD Global Project on Drug
Resistance
Due to difficulties in collecting comparable data
from different countries/regions and in order to assist
National Tuberculosis Programmes  (NTPs) in
establishing policies for drug resistance surveillance
and programme monitoring, the WHO and IUATLD
proposed, in 1994, a global tuberculosis surveillance
programme8. The objectives of this programme
included (i) to collect data on the global extent and
severity of anti-TB drug resistance in a standardized
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manner at country/regional level; (ii) to monitor drug
resistance levels in countries identified as a priority
for assistance; and (iii) proper bacteriological
methodology in national laboratories through an
international system of proficiency testing.
Guidelines for the performance of anti-TB drug
resistance surveillance were developed including
standard definitions and procedures for
implementation8.
The global drug resistance scenario
During the period 1994-2002, a total of 109
surveillance projects on anti-TB drug resistance in
90  countries were completed. This included 43 per
cent of all the countries in the world covering
approximately 42 per cent of the world’s population
and 34 per cent of the reported TB cases 9. However,
the Global Project had the highest coverage in the
Americas (95%) and the Western Pacific Region
(49%), while the lowest coverage was observed in
South-East Asia (11%). The median prevalence of
MDR-TB in new cases of tuberculosis was 1.1 per
cent (range 0-14.2%). Among previously treated cases
median prevalence of resistance to any drug was 33.4
per cent (range 0-93.8%). The median prevalence of
MDR-TB among treated cases was 7.0 per cent,
ranging from 0 per cent in eight geographical settings
to a maximum of 58.3 per cent in Oman 9.
Analysis of almost 90,000 strains from countries
between 1994 and 2002 confirmed that, globally,
more strains were resistant to INH than to any other
drug (range 0-42%). In general, INH and SM
resistance was more prevalent than RMP or EMB
resistance. In previously treated cases, the proportion
of strains resistant to three or four drugs was
significantly greater than among new cases. This
relationship was found globally as well as regionally
and suggested amlification of resistance. It also
appeared that INH and SM monoresistance are the
main gateways to acquisition of additional resistance.
The main findings of the Global Tuberculosis
Programme are summarized in Table I.
Drug resistance studies in India
Although drug resistance in tuberculosis has been
reported frequently during the last four decades, the
available information from India is localized,
inaccurate or incomplete10. In order to formulate a
national treatment policy, reliable and periodic
updates on the prevalence of drug resistance for the
entire country is needed, which would serve as an
indication of the transmission of drug resistant
organisms as well as the efficacy of the NTP. In view
of the large size of the country and several other
administrative as well as financial constraints,
surveys of drug resistance at a national level are
logistically difficult to undertake. Most of the
published reports on drug resistance in India, with
the exception of studies reported from the
Tuberculosis Research Centre (TRC) in
Table I. Global antituberculosis drug resistance situation
Drug Range (%) of drug resistance during the period
1994-1997 1996-1999 1999-2002
Initial Acquired Initial Acquired Initial Acquired
Isoniazid 1.5-31.7 5.3-69.7 0.0-28.1 0.0-81.3 0.0-42.6 0.0-71.0
Streptomycin 0.3-28.0 0.0-82.6 0.3-32.4 0.0-52.4 0.0-51.5 0.0-73.1
Rifampicin 0.0-16.8 0.0-57.9 0.0-15.8 0.0-50.0 0.0-15.6 0.0-61.4
Ethambutol 0.0-9.9 0.0-29.6 0.0-11.1 0.0-32.1 0.0-24.8 0.0-54.2
MDR 0.0-14.4 0.0-58.0 0.0-14.1 0.0-48.2 0.0-14.2 0.0-58.3
(range)
MDR, multi drug resistance
Source: Ref. 9
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Chennai11-17, the National Tuberculosis Institute (NIT)
in Bangalore18,19 and a few others10, are deficient in
several aspects, such as lack of standardized
methodology, improper elicitation of previous
treatment history, sample selection, non-uniformity
in bacteriological procedures, sub-standard drug
powders used for susceptibility testing and lack of
quality assurance studies10.
Initial drug resistance in India
The Indian Council of Medical Research (ICMR)
undertook drug resistance studies during 1965-67 in
nine urban areas of the country13,14. However, this
exercise was not a surveillance study and did not use
strict sampling techniques, the centres being selected
more for logistic considerations than for
epidemiological reasons. Sputum specimens collected
from all patients attending chest clinics were tested
for drug susceptibility to streptomycin, isoniazid, para
amino salicyctic acid (PAS) and thioacetazone. The
first study was on patients who had denied any history
of previous treatment, while in the second study,
patients with and without previous chemotherapy
were included. The results showed that in the first
study resistance to isoniazid ranged from 11-20 per
cent, to streptomycin from 8-20 per cent and to both
drugs from 4-11 per cent. The second study showed
resistance to isoniazid to range from 15-69 per cent,
to streptomycin from 12-63 per cent and to both drugs
from 5-58 per cent. Further, the level of drug
resistance was proportional to the duration of previous
treatment.
A decade later, a study at the Government Chest
Institute and Chest Clinic of Government Stanley
Hospital (GCI-SH), Chennai20 yielded results similar
to those in earlier ICMR surveys, indicating that the
prevalence of initial drug resistance had not risen
during the span of ten years. However, both the above
studies were undertaken in the pre-rifampicin era and
are not of relevance in the present setting.
During the 1980s, though the levels of initial drug
resistance to isoniazid and streptomycin in 11 reports
(Table II) were similar to those in the earlier studies,
rifampicin resistance was observed in all the centres
studied except Gujarat 15, 17-19, 21-23.  The level of MDR-
TB in all the centres (except Wardha) was observed
to be less than 5 per cent. The reason for the
emergence of rifampicin resistance during this period
may be the introduction of short course chemotherapy
(SCC) regimens containing rifampicin. Further, a
higher level of initial drug resistance to isoniazid
(32.9%) was observed among the rural population in
Kolar19 compared to the urban patients, contradicting
a Korean study24, where a much higher level of initial
resistance was seen among urban patients, attributed
to easy access to the antituberculosis drugs. There
was also an increase in the proportion of initial drug
resistance to rifampicin (4.4%) encountered in this
rural population in Karnataka.
In the early 1990s, a retrospective study done at
New Delhi showed a high level of initial drug
resistance to isoniazid (18.5%) and a low level of
resistance to rifampicin25.
Data on the prevalence of drug resistance from
the Army Hospital, Pune showed a very low level of
initial resistance to isoniazid and the authors have
explained that this lower level of drug resistance in
this population could be due to the minimal chance
of indiscriminate exposure of anti-TB agents prior
to reporting to the hospital26.  However, it should be
emphasized that several of these reports, except those
from the TRC, NTI and the Armed Forces Group,
may have inherent limitations due to flaws in
methodology and hence need to be interpreted with
caution.
TRC studies on prevalence of primary drug
resistance
(i) Controlled clinical studies: Drug resistance data
from controlled clinical trials on SCC with
rifampicin-containing regimens conducted at the
TRC, Chennai involving almost 3500 patients over
the last 3 decades is shown in the Figure.  For
isoniazid, the resistant rate ranged from 10-16 per
cent and for streptomycin from 8-13 per cent.
Resistance to rifampicin started appearing in 1990s
and still remains at around 1 per cent. Resistance to
both isoniazid and rifampicin (MDR) is 1 per cent or
less.  These figures could be considered to represent
an accurate picture of true primary resistance in view
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Table II.  Summary of studies on initial drug resistance among M.tuberculosis isolates in India
Location Period No. of Any resistance (%)  to
isolates
S H R SH HR
9 Centres-ICMR I13 1964-65 1838 14.7 12.5 ND 6.5 ND
9 Centres-ICMR II14 1965-67 851 13.8 15.5 NA ND
GCI-SH, Chennai20 1976 254 14.2 15.4 ND 4.7 ND
Bangalore18 1980’s 436 5.7 17.4 3.0 3.9 1.1
Wardha21 1982-89 323 14.9 21.4 8.0 8.0 5.3
Gujarat22 1983-86 570 7.4 13.8 0.0 4.2 0.0
Bangalore19 1985-86 588 4.8 17.3 2.9 3.0 1.4
North Arcot15 1985-89 2779 11.6 21.3 1.7 8.0 1.6
Pondicherry15 1985-91 1841 8.1 10.8 1.0 3.7 0.8
Kolar19 1987-89 292 5.1 32.9 4.4 4.1 3.4
Raichur15 1988-89 244 11.4 19.3 3.3 6.6 3.3
North Arcot* 1989-90 241 12.9 2.5 1.7
North Arcot* 1989-98 747 19.0 11.8 4.4
Jaipur23 1989-91 1009 7.6 10.1 3.0 1.7 0.9
New Delhi25 1990-91 324 ND 18.5 0.6 ND 0.6
Military Hosp, Pune26 1992-93 473 8.2 3.2 4.0 2.1 1.0
Tamil Nadu state11 1997 384 6.8 15.4 4.4 4.4 3.4
North Arcot12 1999 282 12.4 23.4 2.8 8.5 2.8
Raichur12 1999 278 7.2 18.7 2.5 4.0 2.5
Wardha** 2000 197 7.6 15.0 0.5 3.0 0.5
Jabalpur** 2002 273 7.0 16.5 1.8 2.6 1.1
*Tuberculosis Research Centre, unpublished data
**Tuberculosis Research Centre, interim findings, unpublished data
S, streptomycin; H, isoniazid; R, rifamicin;  ND, not done
of the detailed and repeated questioning methods used
for eliciting history of previous treatment from the
patients.
(ii) DRS studies: As part of the WHO/IUATLD
Global DRS programme, the Tuberculosis Research
Centre, Chennai, undertook studies during 1997-99
in Tamil Nadu State11 as well as the districts of North
Arcot and Raichur12. These studies revealed initial
resistance to rifampicin to range from 2.5-4.4 per cent
while the prevalence of MDR-TB was around 3 per
cent. The results of another study in the Wardha
district of Maharashtra revealed resistance to
isoniazid, rifampicin and to both drugs to be 15.2,
0.5 and 0.5 per cent respectively (TRC, unpublished
data). Interim results of a recently concluded study
in the Jabalpur district of Madhya Pradesh showed
initial resistance to isoniazid, rifampicin and to both
drugs to be 16.1, 1.8 and 1.1 per cent, respectively
(TRC, unpublished data). Since 1999, TRC has
carried out several operational research studies in the
model DOTS area in Tiruvallore district of Tamil
Nadu, including measurement of drug resistance
among patients living in the trial area. Interim data
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(1999-2003) revealed resistance to isoniazid and
MDR to be 11.8 and 1.6 per cent respectively (TRC
unpublished). Likewise, a study on drug resistance
carried out on HIV/TB patients (2000-02) revealed
resistance to isoniazid and MDR to be 13 and 4.3 per
cent respectively (TRC, unpublished).
Studies on DRS have also been undertaken by the
National Tuberculosis Institute (NTI) in the districts
of Mysore (2001), Hoogly (2003), Mayurghanj
(2003) and Naogaon (2003) and also in Bangalore
city where MDR TB levels amongst patients with no
history of previous treatment were observed to be
1.2, 3.0, 0.7, 7.2 and 2.2 per cent respectively (NTI,
unpublished).
Acquired drug resistance in India
The rates of acquired resistance are invariably
higher than those of initial resistance, though data on
acquired resistance are limited.  The findings of studies
on acquired resistance are shown in Table III. The
longitudinal trend of drug resistance noted by Trivedi
and Desai22 during the 1980s in Gujarat showed that
in chronically ill, treatment failure or relapsed patients,
resistance to rifampicin increased from 2.8 per cent in
1980 to 37.3 per cent in 1986 and to isoniazid from
34.5 to 55.8 per cent.  From this study it was presumed
that high level of rifampicin resistance was almost
entirely acquired. During this period MDR-TB was of
the order of 30 per cent.
In the course of a study conducted by the TRC in
North Arcot district to compare the efficacy of SCC
with conventional (non-SCC) chemotherapy, it was
found that frequency of acquired drug resistance was
67 per cent to isoniazid, 26 per cent to streptomycin
and 12 per cent to rifampicin; in addition, 11 per cent
of the strains tested were resistant to both isoniazid
and rifampicin16.  A New Delhi study25 in the 1990s
also showed a higher level of acquired resistance to
isoniazid and rifampicin which is almost similar to
that of the Gujarat report22. A study conducted by
the Institute of Thoracic Medicine, Chennai in four
District Tuberculosis Centres of Tamil Nadu, showed
that acquired resistance was 63 per cent, out of which
23.5 per cent was resistance to single drug and 39.5
per cent to more than one drug.  Resistance to
isoniazid and rifampicin (MDR-TB) was reported in
20.3 per cent27.
Studies undertaken by the TRC, Chennai during
1997-2000 in the entire state of Tamil Nadu11, North
Arcot and Raichur districts12   as well as in Wardha
and Jabalpur (unpublished) revealed the incidence of
MDR-TB to vary from 25-100 per cent.  However,
these data are based on very small numbers of
patients.  Since these studies were not designed to
obtain a true picture of acquired resistance in these
areas, the results presented should be interpreted with
caution. However, DRS data obtained from 440
patients from the model DOTS area in Tiruvallore
district of Tamil Nadu (1999-2003) revealed the
incidence of MDR TB to be 11.8 per cent
Fig. Prevalence of primary drug resistance TRC studies* - (1974-2001). After the introduction of rifampicin in Controlled Clinical
Trials at Tuberculosis Research Centre (TRC). MDR, multidrug resistance (R,H); RIF, rifampicin; STREP, streptomycin; INH,
isoniazid.
383
(TRC, unpublished) and in the HIV, TB study, MDR
TB was 5.9 per cent, based on 37 patients (2000-02,
unpublished).
A recently concluded study, with International
Clinical Epidemiology Network (INCLEN) funding,
in eight different settings in India (two in
Maharashtra, three in Tamil Nadu and one each in
Uttar Pradesh, Kerala and Delhi) is expected to yield
considerable data on the magnitude of drug-resistant
tuberculosis in the country.
Management of multi-drug resistant tuberculosis
The emergence of drug resistant strains is known
to reduce the efficacy of treatment. Strains resistant
to isoniazid and/or streptomycin  neither pose a major
problem nor affect the result of treatment in a big
way provided proper regimens are used. The currently
available short-course regimens of six months
duration cure 94-97 per cent of patients with
resistance to streptomycin, isoniazid or to both
drugs28. On the contrary, the outcome of treatment
of patients infected with organisms resistant to
rifampicin and isoniazid (MDR) have a high rate of
treatment failure. Studies at the TRC had reported
that 35 of 38 patients with MDR failed to respond
with conventional regimens29. Patients infected with
MDR strains require longer duration of therapy and
may die of tuberculosis or continue to have active
tuberculosis despite optimal therapy.  In about 170
patients with MDR-TB over a 12-year period (1986-
97) at the TRC, Chennai, only one third had a
favourable outcome and another one-third had died30.
A retrospective analysis reported from South
Korea on  patients with MDR-TB treated with at least
four drugs to which they had not been exposed to
before, or to which they were known to be susceptible,
82.5 per cent of  patients followed up responded to
treatment and there were no subsequent relapses or
TB-related deaths, when followed up for 17 months31.
A recent study from the developed countries reported
that the cure rates for patients with MDR-TB
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Table III.  Summary of studies on acquired drug resistance among M. tuberculosis isolates in India
Location Period No. of Any resistance  (%)  to
isolates
H R HR
Gujarat22 1980-86 1574 47.7 28.3 —
Gujarat22 1983-86 1259 81.1 33.0 30.2
Wardha21 1982-89 302 47.0 12.6 9.6
North Arcot16 1988-89 560 67.0 12.0 10.9
Raichur17 1988-89 111 52.3 17.1 17.1
New Delhi25 1990-91 81 60.5 33.3 33.3
Tamil Nadu (4 districts)27 1996 162 — — 20.3
Tamil Nadu State11 1997 16 (50.0) (25.0) (25.0)
North Arcot12 1999 16 (81.0) (69.0) (69.0)
Raichur12 1999 11 (100.0) (100.0) (100.0)
Wardha* 2000 9 (78.0) (78.0) (78.0)
Jabalpur* 2002 31 87.1 80.6 80.6
Brackets indicate that the percentage is based on isolates less than 25
*TRC, unpublished interim findings
H, isoniazid; R, rifampicin
Superscript numerals indicate reference nos.
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increased from 56 per cent in 1973-1983 to
84 per cent in 1983-2000, with the improvement
attributed to the use of fluoroquinolones and
surgery32. Recent studies at the TRC, Chennai have
shown promising results with the use of added
ofloxacin in the regimens in treating MDR-TB. While
interim reports appear promising, a long-term follow
up is needed to draw valid conclusions (TRC,
unpublished observations). The fluoroquinolones
have been shown to have marked anti-mycobacterial
activity and are being increasingly used in the
treatment of MDR-TB. However, this class of drugs
is also widely used for a variety of respiratory and
other infections. Caution has to be exercised as
indiscriminate use will lead to the development of
resistance to this class of drugs also.
The value of some of the older drugs in the
treatment of MDR-TB has to be re-emphasized.
Many of the younger patients of today have never
received PAS or thioacetazone in the past and these
drugs can be used with success. In the recent past,
there have been a few reports of the value of β-
lactam antibiotics used along with β-lactamase
inhibitors33, rifabutin34 and recombinant human
interleukin-235 in the management of MDR-TB.
However, these studies are all based on small
numbers of patients and need to be evaluated
further in well designed controlled clinical trials.
Conclusions
In view of the results presented above, there is
no clear evidence of an increase in the prevalence
of initial drug resistance in India over the years.
However, relatively high prevalence of acquired
resistance has been reported from Gujarat, New
Delhi, Raichur and North Arcot districts. When
compared to  the  global  prevalence of  drug
resistance, initial drug resistance is found to be
marginally less while that of acquired resistance
is much higher in India in specialized settings. The
magnitude of drug resistance problem to a large
extent  i s  due to  acquired res is tance.   The
prevalence of MDR-TB also is found to be at a
low level in most of the regions of India. However,
these studies need to be repeated in different
regions and in diverse settings to reconfirm this
belief. TRC, Chennai and NTI, Bangalore have been
working closely with central TB division and
finalized recently a protocol for carrying out drug
resistance surveillance (DRS) at the state level. The
central TB division has been providing assistance to
investigators in carrying out DRS at their respective
places. As a follow-up, DRS protocols have been
finalized for two large Indian states, namely, Gujarat
and Maharashtha and the results are expected to be
known in 2005. Similar efforts are underway for two
other states, namely, Andhra Pradesh and Orissa with
funds provided by the WHO Global Fund for AIDS,
tuberculosis and malaria (GFATM).
A strong tuberculosis programme that can reduce
the incidence of drug resistance in the community
and particularly directly observed therapy (DOTS)
which is cost effective, will prove to be effective in
treatment completion and in turn prove to be effective
against generation of resistant strains. Newer drugs
for tuberculosis are unlikely to come up in the near
future and hence the key to success remains in
adequate case finding, prompt and correct diagnosis
and effective treatment of infective patients including
careful introduction of second-line drugs to which
the patient is susceptible.
Apart from a strong tuberculosis control
programme, there is also need for better and more
rapid diagnostic methods, a continuous or periodic
survey of drug resistance, with an emphasis on
internal quality control and external quality
assessment, which will provide information on the
type of chemotherapy to be used for the treatment of
patients and also serve as a useful parameter in the
evaluation of current and past chemotherapy
programmes.
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